Summarized by Masters of Longevity from Longevity Technology.
Report on a potential disease-modifying knee osteoarthritis therapy entering formal regulatory assessment in the UK, with trial imaging and symptom data summarized.
Key Takeaways
- Lorecivivint entered formal review with the UK regulator based on Biosplice's clinical data.
- Phase 3 OA-07 imaging showed maintained or improved medial joint space over two years versus placebo.
- Pain and function measures improved by 6–12 months compared with placebo, with an injection safety profile similar to placebo.
